Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $107K rose 8.1% year over year, ahead of the -11.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 40.8% from the prior quarter. Over 3 fiscal years it compounded at +42.8% a year.
Context
- Depreciation & amortization amounted to 21.0% of revenue in FY2025, up 14.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.1% holds above the trailing-twelve-month pace of -11.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 428K USD
- Year-over-year change
- +3.9%
- 4-year CAGR
- -32.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 428K | +3.9% |
| FY2024 | 2024-12-31 | 412K | +16.1% |
| FY2023 | 2023-12-31 | 355K | +141.5% |
| FY2022 | 2022-12-31 | 147K | -92.7% |
| FY2021 | 2021-12-31 | 2.02M | — |
Depreciation & Amortization vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 depreciation & amortization of $379K is the 8th largest of the 10 companies compared; the peer median is $2.42M.
- Its year-over-year change of -11.0% is the 9th highest of 10, against a peer median of +6.7%.
- Depreciation & amortization amounts to 19.9% of revenue for DNTH, versus a peer median of 26.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M | +5.4% | +140.9% | 47.7% |
| LTM Mar 2026 | $3.08M | +114.9% | +496.0% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.71M | +9.6% | +30.9% | — |
| LTM Mar 2026 | $2.43M | +1.2% | +1.2% | 1.0% | |
| LTM Mar 2026 | $2.42M | +13.1% | +32.0% | 136.2% | |
| FY2025 | $704K | +6.7% | -11.4% | 1100.0% | |
| LTM Jun 2026 | $652K | +130.4% | — | — | |
| LTM Jun 2026 | $379K | -11.0% | +42.8% | 19.9% | |
| LTM Sep 2026 | $378K | -10.0% | +28.4% | 5.3% | |
| LTM Mar 2026 | $305K | -36.9% | +1.9% | 0.6% | |
| Peer median (excluding DNTH) | $2.42M | +6.7% | +29.7% | 26.5% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.14M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| Deferred Income Tax | 0 | 0 | (661K) | 0 | 0 |
| Stock-Based Compensation | 0 | 1.52M | 2.9M | 12.89M | 22.79M |
| Change in Working Capital | (1.53M) | (1.65M) | 4.86M | (351K) | 16.73M |
| Accounts Receivables | 0 | (4.16M) | 5.16M | 0 | 755K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (720K) | 2.28M | 661K | 8.19M | 11.28M |
| Other Working Capital | (806K) | 229K | (959K) | (8.54M) | 4.69M |
| Other Non-Cash Items | 11.11M | (606K) | (762K) | (6.17M) | (6.67M) |
| Operating Cash Flow | (59.53M) | (29.07M) | (36.86M) | (78.18M) | (129.06M) |
| Capital Expenditures | (1.26M) | (139K) | (110K) | (105K) | (213K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (45.31M) | (61.68M) | (57.42M) | (413.71M) | (435.01M) |
| Sales of Investments | 90M | 2M | 77.79M | 127M | 312.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 43.43M | (59.82M) | 20.25M | (286.81M) | (122.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.6M | 0 | 72M | 269.2M | 280.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.32M) | 61.57M | (13.58M) | 0 |
| Financing Cash Flow | 89.6M | 96.68M | 133.57M | 255.62M | 280.13M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 73.5M | 7.79M | 116.97M | (109.37M) | 28.23M |
| Free Cash Flow | (60.8M) | (29.21M) | (36.97M) | (78.29M) | (129.27M) |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.